Lessons Learned: Operationalizing Chimeric Antigen Receptor T-Cell Therapy in the Community Oncology Private Practice Healthcare Setting.

Authors

Martie M Steinfeld, Xiaoxiao Zhang, Ashley Todd, Kathleen L Murphy

Published in

Clinical journal of oncology nursing. Volume 30. Pages E73-E79. Jul 08, 2026.

Abstract

Chimeric antigen receptor (CAR) T-cell therapy is an established therapy for relapsed or refractory hematologic malignancies. Traditionally, it has been administered in outpatient or inpatient settings at urban academic medical centers that are affiliated with established stem cell transplantation programs. Tennessee Oncology has successfully treated more than 30 patients with CAR T-cell therapy since August 2024 in the community oncology outpatient setting.
This article reviews key discoveries and lessons learned in creating a cellular therapy program in a nontraditional setting. Tennessee Oncology approached this endeavor with confidence, not fully understanding the complexity of transitioning from concept to care for the first patient.
Oncology nurses across several roles collaborated, planned, developed, implemented, and educated staff about CAR T-cell therapy across 24 months. The first 12 months were spent without a patient in the program, to assist other facilities in operationalizing their first CAR T-cell therapy program.
Building an institutional CAR T-cell therapy program from inception is a resource-intensive and iterative process; however, successful execution can be achieved through unwavering stakeholder investment and a highly skilled specialized nursing workforce.

PMID:
42462103
Bibliographic data and abstract were imported from PubMed on 17 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.